Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07814417 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Olomorasib (LY3537982) in Participants With Advanced Colorectal Cancer and a KRAS G12C Mutation

Name: A Study of Olomorasib (LY3537982) in Participants With Advanced Colorectal Cancer and a KRAS G12C Mutation — clinical trial record (NCT07814417)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 2

SponsorEli Lilly and Company

Started2026-10

View on ClinicalTrials.gov ↗

The main purpose of this study is to evaluate how well olomorasib is tolerated and what side effects may occur when combined with other interventions in participants with Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C-mutant, locally advanced colorectal cancer (CRC) that cannot be removed with surgery or has spread to other parts of the body. Blood tests will be performed to investigate how the body processes the study drug.

Trial Details

NCT Number	NCT07814417
Lead Sponsor	Eli Lilly and Company
Conditions	Colorectal Neoplasms
Enrollment	50 participants
Start Date	2026-10
Primary Completion	2028-11 (estimated)
Study Completion	2028-11 (estimated)
Updated on ClinicalTrials.gov	2026-09-11